Valuation dashboard for Dr. Reddy's Laboratories Limited (RDY) with P/E 30.37, P/B 2.62, EV/EBITDA 13.66 and dividend yield 0.66%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products.
Analysis Summary
Dr. Reddy's Laboratories Limited reported revenue of 353.47B INR in the most recent fiscal year, growing at a 5-year CAGR of 168.0%. Net income reached 45.09B INR, with a 186.8% 5-year CAGR.
Trailing-twelve-month margins: gross margin 50.2%, operating margin 10.6%, net margin 10.0%.
At the current price of $12.32, RDY trades at a P/E of 30.37 and an ROE of 12.20%. Market capitalisation stands at $10.3B, placing it among large-cap names.
Balance sheet quality for RDY: current ratio of 1.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 30.37 |
| Price / Book | 2.62 |
| EV / EBITDA | 13.66 |
| Dividend Yield | 0.66% |
Valuation Models
| DCF Fair Value | $12.66 |
| vs Current Price | +2.7% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| RDY | Dr. Reddy's Laboratories Limited | $10.2B | 30.37 | 2.62 | 12.2% |
| RVMD | Revolution Medicines, Inc. | $43.9B | 16.72 | -69.3% | |
| NBIX | Neurocrine Biosciences, Inc. | $14.3B | 20.31 | 3.92 | 21.1% |
| EXEL | Exelixis, Inc. | $14.9B | 17.75 | 7.94 | 42.5% |
| ENSG | The Ensign Group, Inc. | $10.0B | 26.92 | 4.08 | 16.5% |
| BMRN | BioMarin Pharmaceutical Inc. | $11.1B | 150.47 | 1.75 | |
| ELAN | Elanco Animal Health Incorporated | $11.2B | 1.68 | -3.0% | |
| EHC | Encompass Health Corporation | $11.9B | 19.26 | 4.56 | 25.0% |
Price
| Price | $12.32 |
| Market Cap | $10.3B |
| Exchange | NYSE |
| Country | IN |
Profitability
| Return on Equity | 12.20% |
| Return on Invested Capital | 8.10% |
| Return on Assets | 7.94% |
| Gross Margin | 50.18% |
| Operating Margin | 10.64% |
| Net Margin | 10.00% |
Related companies: BMRN · EHC · ELAN · ENSG · EXEL · NBIX · RVMD
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of RDY: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks